CLEAN : Pfizer strikes licensing deal for potential Covid treatment (2)

The video discusses a voluntary treatment candidate with involvement from the World Health Organization. It covers the quality assurance of generic medicines and details the license agreement between Sizer and MPP, allowing selected manufacturers to supply drugs to 95 countries. The medicine is primarily for at-risk groups to prevent severe cases and hospitalizations. MPP is responsible for selecting companies to manufacture the medicine, with a focus on a quick review process, though exact timelines for drug authorization and availability remain uncertain.

What is the intended use of the medicine for people at risk?

What is the timeline for the companies to become candidates for supplying the drugs?